Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$131.19
+0.7%
$131.34
$110.33
$141.23
$226.73B0.76.01 million shs4.84 million shs
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
$6.82
+0.1%
$6.61
$5.64
$16.76
$697.56M-1.262.15 million shs1.76 million shs
Evotec AG stock logo
EVO
Evotec
$3.61
-1.9%
$4.04
$2.84
$5.64
$1.31B1.6764,308 shs56,668 shs
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
$2.84
-3.1%
$2.61
$1.05
$3.31
$628.96M0.982.76 million shs2.98 million shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abbott Laboratories stock logo
ABT
Abbott Laboratories
-1.02%-0.81%+5.26%-3.60%+17.41%
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
+0.89%+15.42%+6.41%+3.50%-51.08%
Evotec AG stock logo
EVO
Evotec
-2.13%-3.41%-13.62%-9.58%+12.88%
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
-0.34%+6.16%+14.01%0.00%+30.22%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abbott Laboratories stock logo
ABT
Abbott Laboratories
4.9737 of 5 stars
3.54.04.24.52.52.52.5
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
2.1531 of 5 stars
3.62.00.00.02.41.70.0
Evotec AG stock logo
EVO
Evotec
1.7358 of 5 stars
3.32.00.00.02.30.00.6
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
3.4748 of 5 stars
4.52.00.00.02.93.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abbott Laboratories stock logo
ABT
Abbott Laboratories
2.91
Moderate Buy$144.4710.12% Upside
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
3.13
Buy$25.29270.76% Upside
Evotec AG stock logo
EVO
Evotec
2.50
Moderate Buy$5.4049.58% Upside
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
3.00
Buy$8.29191.75% Upside

Current Analyst Ratings Breakdown

Latest EVO, DAWN, TSHA, and ABT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/18/2025
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight ➝ Overweight$25.00
8/14/2025
Evotec AG stock logo
EVO
Evotec
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$8.00 ➝ $7.00
8/13/2025
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$7.50 ➝ $8.00
8/12/2025
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$9.00 ➝ $10.00
8/6/2025
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$18.00 ➝ $16.00
8/6/2025
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$36.00 ➝ $25.00
7/18/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$147.00 ➝ $142.00
7/18/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$142.00 ➝ $141.00
7/18/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$148.00 ➝ $145.00
7/18/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$143.00 ➝ $145.00
7/17/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 8/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$41.95B5.44$6.63 per share19.79$29.20 per share4.49
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
$131.16M5.33N/AN/A$4.50 per share1.52
Evotec AG stock logo
EVO
Evotec
$862.40M1.49N/AN/A$2.70 per share1.34
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
$8.33M73.19N/AN/A$1.16 per share2.45
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$13.40B$7.9816.4422.902.4732.43%18.32%10.71%10/15/2025 (Estimated)
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
-$95.50M-$0.950.00N/AN/A-50.63%-19.01%-16.99%10/29/2025 (Estimated)
Evotec AG stock logo
EVO
Evotec
-$212.18MN/A0.00N/AN/A-20.14%-16.94%-8.14%11/5/2025 (Estimated)
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
-$89.30M-$0.340.00N/AN/A-1,144.97%-78.44%-44.82%N/A

Latest EVO, DAWN, TSHA, and ABT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
-$0.07-$0.09-$0.02-$0.09$1.61 million$1.99 million
8/5/2025Q2 2025
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
-$0.35-$0.29+$0.06-$0.29$35.55 million$33.91 million
7/17/2025Q2 2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.26$1.26N/A$1.01$11.01 billion$11.14 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$2.361.80%N/A29.57%54 Years
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
N/AN/AN/AN/AN/A
Evotec AG stock logo
EVO
Evotec
N/AN/AN/AN/AN/A
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
N/AN/AN/AN/AN/A

Latest EVO, DAWN, TSHA, and ABT Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/13/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
quarterly$0.591.73%7/15/20257/15/20258/15/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.25
1.82
1.30
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
N/A
9.65
9.53
Evotec AG stock logo
EVO
Evotec
0.42
1.58
1.49
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
0.17
12.48
12.48

Institutional Ownership

CompanyInstitutional Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
75.18%
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
87.95%
Evotec AG stock logo
EVO
Evotec
5.81%
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
77.70%

Insider Ownership

CompanyInsider Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.46%
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
6.20%
Evotec AG stock logo
EVO
Evotec
N/A
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
3.78%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abbott Laboratories stock logo
ABT
Abbott Laboratories
114,0001.74 billion1.73 billionOptionable
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
60102.43 million96.08 millionOptionable
Evotec AG stock logo
EVO
Evotec
4,827355.11 millionN/ANot Optionable
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
180214.66 million206.55 millionOptionable

Recent News About These Companies

FY2025 Earnings Forecast for TSHA Issued By Chardan Capital
FY2025 Earnings Estimate for TSHA Issued By Chardan Capital
Cantor Fitzgerald Issues Negative Forecast for TSHA Earnings
FY2025 EPS Forecast for Taysha Gene Therapies Cut by Analyst
Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $8.00
Taysha Gene Therapies Advances Rett Syndrome Trials

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Abbott Laboratories stock logo

Abbott Laboratories NYSE:ABT

$131.19 +0.92 (+0.71%)
Closing price 03:59 PM Eastern
Extended Trading
$131.66 +0.47 (+0.36%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Day One Biopharmaceuticals stock logo

Day One Biopharmaceuticals NASDAQ:DAWN

$6.82 +0.01 (+0.15%)
Closing price 04:00 PM Eastern
Extended Trading
$6.82 +0.00 (+0.07%)
As of 05:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Evotec stock logo

Evotec NASDAQ:EVO

$3.61 -0.07 (-1.90%)
Closing price 04:00 PM Eastern
Extended Trading
$3.62 +0.02 (+0.42%)
As of 06:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Taysha Gene Therapies stock logo

Taysha Gene Therapies NASDAQ:TSHA

$2.84 -0.09 (-3.07%)
Closing price 04:00 PM Eastern
Extended Trading
$2.80 -0.04 (-1.41%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.